You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Claritev Corporation raised full-year revenue guidance to $1.038 billion to $1.043 billion and adjusted EBITDA guidance to $625 to $630 million, while expecting at least $1.1 billion of revenue in 2027.
Claritev reported revenue increased $22.4 million, or 9.1%, for the three months ended September 30, 2026, while operating income rose 104.9% to 20,627 (in thousands). IT general-control material weaknesses remained unremediated, leaving disclosure controls ineffective.
Claritev Corporation reported Q3 2026 revenues of $268.3 million, up 9.1%, and a net loss of $61.8 million, while raising 2026 revenue guidance to $1.038 billion to $1.043 billion. It also introduced preliminary 2027 revenue expectations of $1.1 billion.
Claritev Corporation appointed Jennifer Main as a Class II director and Audit Committee member on October 15, 2026, filling a newly created seat; Jason Kap ceased serving on the Audit Committee.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Claritev posted Q2 revenue of $257.5M (up 6.6% YoY) with Adjusted EBITDA of $155.8M, raised full-year revenue guidance to $1.00B–$1.02B and Adjusted EBITDA to $610M–$620M, and reported $74M of H1 bookings tracking ahead of its $100M full-year target, though GAAP results remain in a net loss and Adjusted EBITDA margin compressed to 60.5%.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Cash Conversion Ratio non-GAAP | 42% | Six Months Ended June 30, 2026 | — |
| Adjusted earnings per share non-GAAP | $1.41 | Three Months Ended June 30, 2026 filing | — |
| Adjusted EBITDA non-GAAP | $302.71M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA Margin non-GAAP | 60.5% | Q2 2026 | — |
| Adjusted net income non-GAAP | $23.98M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net loss -59.23M
+85.91M Amortization of intangible assets
+2.57M Legal expenses associated with antitrust matters
+309K Loss on disposal of assets, including right-of-use assets
+9.25M Transformation costs
+25K Other expenses, net
+0K Integration expenses
+0K Transaction costs related to refinancing transaction
+9.53M Stock-based compensation, including cRSUs
-24.39M Estimated tax effect of adjustments
= Adjusted net income 23.98M
|
|||
| EBITDA | $251.84M | Six Months Ended June 30, 2026 | — |
| Free cash flow non-GAAP | -$37.96M | Six Months Ended June 30, 2026 | — |
| Unlevered Free Cash Flow non-GAAP | $126.25M | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CTEV
this stock
Claritev Corp
|
$457.95M | -37.3% | +3.7% | — | 4.5% |
|
VEEV
Veeva Systems Inc
|
$48.82B | +35.1% | +28.1% | 49.4 | 2.4% |
|
PMDIY
Pro Medicus Ltd.
|
$14.81B | -14.6% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$14.17B | +90.1% | +28.2% | 38.7 | 5.8% |
|
TEM
Tempus AI, Inc.
|
$13.06B | +21.3% | +83.4% | — | 13.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Claritev reported revenue increased $22.4 million, or 9.1%, for the three months ended September 30, 2026, while operating income rose 104.9% to 20,627 (in thousands). IT general-control material weaknesses remained unremediated, leaving disclosure controls ineffective.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CTEV | +18.1% | +21.3% | +23.3% | +11.8% | -37.3% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +15.5% | +22.4% | +22.8% | +11.9% | -47.9% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
